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ABSTRACT 
Objective To estimate the economic burden to the health service of surgical site 
infection following caesarean section and to identify potential savings achievable 
through implementation of a surveillance programme. 
Design Economic model to evaluate the costs and benefits of surveillance from 
community and hospital healthcare providers’ perspective.  
Setting England.   
Participants Women undergoing caesarean section in National Health Service 
hospitals.  
Main outcome measure Costs attributable to treatment and management of 
surgical site infection following caesarean section.  
Results The costs (2010) for a hospital carrying out 800 caesarean sections a year 
based on infection risk of 9.6% were estimated at £18,914 (95% CI 11,521 to 
29,499) with 28% accounted for by community care (£5,370).  With inflation to 2019 
prices, this equates to an estimated cost of £5.0m for all caesarean sections 
performed annually in England 2018-19, approximately £1,866 and £93 per infection 
managed in hospital and community respectively.  The cost of surveillance for a 
hospital for one calendar quarter was estimated as £3,747 (2010 costs).   
Modelling a decrease in risk of infection of 30, 20 or 10% between successive 
surveillance periods indicated that a variable intermittent surveillance strategy 
achieved higher or similar net savings than continuous surveillance. Breakeven was 
reached sooner with the variable surveillance strategy than continuous surveillance 
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when the baseline risk of infection was 10 or 15% and smaller loses with a baseline 
risk of 5%.   
Conclusion Surveillance of surgical site infections after caesarean section with 
feedback of data to surgical teams offers a potentially effective means to reduce 
infection risk, improve patient experience and save money for the health service.   
Strengths and limitations 
• The model estimated both community (28%) and hospital costs (72%), 
providing a more representative estimate of overall economic burden to the 
health service. 
• Time-matching of patients with and without infection according to length of 
post-operative stay provided a more accurate assessment of excess bed-days 
attributable to surgical site infection (2.6 days) than average excess length of 
stay (median difference 5 days) comparison by disentangling the impact of 
prolonged length of stay on increased chance of detecting an infection. 
• Through capture and assessment of the costs and impact of surveillance, our 
model demonstrated the potential for savings through reductions in incidence 
of surgical site infections.  
• Costs were obtained from NHS National Schedule Reference Costs and other 
sources rather than observed expenditure and assumptions made about the 
number of extra midwife and general practitioner appointments resulting from 
infection.  
• The study was based on healthcare utilisation and did not assess direct and 
indirect costs borne by the patients or their carers.    
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INTRODUCTION 
Caesarean section delivery rates have risen in recent years in many Organisation for 
Economic Co-operation and Development (OECD) countries and ranged from 15.5% 
of deliveries in Finland to 53.1% in Turkey in 2015.1  In England caesarean section 
rates have risen from 9% of deliveries in 1980 to 30% in 2018-19.2 
Surgical site infection is a common and potentially serious complication of caesarean 
section with risk of infection of 9-11% reported previously in the UK.3 4  The majority 
of post-caesarean surgical site infections are superficial infections of the skin and 
subcutaneous tissue which can be managed by the community midwife and general 
practitioner.  However, in the UK, 10-13% are more serious deep infections of the 
muscle and fascial layer or organ/space infections (endometritis and reproductive 
tract infections)4-6 which may require readmission to hospital.  As well as causing 
anxiety and pain for the patient, these infections result in costs to the health service 
both in terms of excess length of hospital stay and for treatment of the infections in 
the community.  In very rare instances, a surgical site infection following caesarean 
section can have fatal consequences.7   
The use of surveillance to measure the risk of surgical site infection and feedback of 
results to surgeons has been shown to be effective in reducing the risk of infection.8-
10   However, surveillance of surgical site infection is resource-intensive and studies 
to assess its cost-benefit have not been conducted. The Surgical Site Infection 
Surveillance Service at Public Health England provides national coordination for 
surgical site infection surveillance for hospitals in England.  In 2009 Public Health 
England conducted a multi-centre study of surgical site infection following caesarean 
section to test the feasibility of post-discharge detection methods and establish a 
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national benchmark for infection risk.6  Based on the findings from the study, we 
undertook a further assessment of the economic burden of infection and the potential 
savings achievable through establishing surveillance as a means to stimulate a 
review of clinical practices and direct infection prevention measures. 
 
METHODS 
A cost-benefit model was constructed to estimate the costs to the health service of 
managing surgical site infection post-caesarean section both in hospital and in the 
community.   
Cohort study 
The estimated risk of infection was based on data captured during a multi-centre 
cohort study which followed a protocol with standard case finding methods and 
definitions of infection.6  Of the 4107 women followed-up after caesarean section 
across the 14 National Health Service centres participating in the 2009 study, 9.6% 
(394) developed a surgical site infection meeting the study case definitions.  Overall 
11.2% (44) of infections were organ/space (endometritis and female genital tract 
infections) or deep incisional infections and the remaining 88.3% were superficial 
incisional infections.  In the cohort study, surgical site infections were detected 
during the initial inpatient hospital admission in which the caesarean section was 
performed, at readmission to hospital, in the community by midwives visiting women 
in their own home or via a patient questionnaire at 30 days after the operation.  
According to the study protocol, if an infection was detected via more than one 
method, a hierarchical approach was used to assign detection method such that if a 
patient reported (community treated) infection was also identified by the community 
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midwife or other outpatient visit then the surgical site infection was reported as 
detection by midwife or other hospital healthcare professional respectively.  Similarly, 
if the patient was readmitted, then detection was recorded as ‘at readmission’ rather 
than patient reported or detected by midwife/other healthcare professional. 
Standard case definitions, based on clinical and laboratory findings, were used to 
identify surgical site infection that occurred up to 30 days after the operation.6 11  
Table 1 shows the parameters taken from the cohort study for use in the model.   
Table 1.  Parameters for surgical site infection (SSI) risk used in the model 
Detection method Infection risk 
All methods combined 9.59% 
   Inpatient detected  0.51% 
       Inpatient detected SSI subsequently readmitted 0.05% 
  Readmission detected 0.56% 
  Community Midwife detected 5.31% 
  Self-reported by patient 3.21% 
 
Seven of the participating hospitals repeated the surveillance for a further three-
month period and the risk of infection were compared between these two periods.  
The seven hospitals who repeated the surveillance for a second period carried out a 
total of 1212 operations with 131 infections in the first period (10.8% risk) and 1235 
operations with 89 infections (7.2% risk) in the second period.  A slight but non-
significant increase in infection risk was observed for two of the seven hospitals, 
whereas five hospitals experienced a decrease in infection risk, three of which were 
significant (Figure 1).  The mean reduction in infection risk between the 2 periods 
across all hospitals was -31.2% (range from –73.3 to 19.5%). 
Hospital treatment costs 
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Costs were modelled on a hospital undertaking a three-month period of surveillance 
and conducting 800 caesarean sections per year (the approximate average number 
of operations for hospitals participating in the multi-centre study).   
The length of the initial hospital stay during which the caesarean section was 
performed was derived from data captured during the study.  Rather than a simple 
comparison of length of stay for women with and without a surgical site infection, a 
case-control paired matching approach was used to estimate excess length of stay 
for patients with an infection diagnosed during the inpatient stay.  All controls must 
have had a post-operative length of stay at least as long as the infection free period 
of stay of the paired case.  The total post-operative length of stay of a patient with 
surgical site infection (case) and total length of stay of matched patients without 
infection (controls) was compared.  The mean average of paired differences between 
cases and controls was calculated.  Under the assumption that the exposure to 
infection is from the time of surgery onwards, then the time in hospital before 
caesarean section is assumed not to put the patients at additional risk of surgical site 
infection.  As well as matching controls to the infection free period of the case, we 
selected controls by identifying patients matched on confounders to account for 
varying length of stay (age, antimicrobial prophylaxis, American Society of 
Anesthesiologists physical status score, body mass index category, blood loss, 
diabetes, duration of active labour, duration of operation, urgency of risk category, 
and wound class).   
Case records of patients identified from the cohort study as having been readmitted 
for a surgical site infection were linked to National Health Service (NHS) Digital 
Hospital Episode Statistics© (HES) Admitted Patient Care Records to derive 
9 
 
information on length of readmission stay and diagnostic reason for readmission.  
This enabled additional costs due to readmission to be calculated for: a) the patients 
from the cohort study who had an infection detected during the inpatient period who 
were also readmitted to hospital for further treatment and b) the patients from the 
cohort study whose infection was initially diagnosed at readmission.   
The average cost of excess bed days and readmissions was identified from codes in 
Healthcare Resource Group data (standard groupings of clinically similar treatments 
which use common levels of healthcare resource listed within HES data) assigned to 
each patient hospital spell and linked to the National Schedule Reference Costs (the 
average unit cost to the NHS of providing a defined service, 2010).12   
Community treatment costs 
Community costs of treating and managing surgical site infection were estimated 
based on the assumption of one extra midwife visit, one general practitioner visit and 
one course of antibiotics for each surgical site infection detected by a midwife. For 
patient reported infections this was assumed to be one general practitioner visit and 
one course of antibiotics.  The cost of a community midwife post-natal visit was 
identified from National Schedule Reference Costs and a general practitioner visit 
from Unit Costs of Health and Social Care (Personal Social Services Research Unit).  
Antibiotic costs were obtained from the NHS Drugs Tariff.13  
The proportion of patients in the study with community reported surgical site infection 
accompanied by positive microbiology results was employed to derive model 
parameters for microbiological testing.  Positive microbiology results were recorded 
for 43% of the community midwife detected surgical site infections and 30% of 
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patient reported infections in the cohort study.  Microbiology costs were obtained by 
personal communication with consultant microbiologists from two NHS Trusts. 
Hospital surveillance costs  
Information on the staff time required to conduct a three-month period of surveillance 
and administer patient questionnaires was provided by three hospitals who 
participated in the multi-centre study.  Expenses for other resources (stationery, 
telephone calls, stamps) needed to carry out surveillance were also recorded.  This 
information was used to determine the average cost of surveillance (including gross 
salary costs) for a hospital conducting 800 caesarean sections per year.   
Cost-benefit analysis 
The uncertainty around the overall costs was calculated using the appropriate 
binomial distributions for the number of infections detected based on the proportions 
in the sample from the study and the reference prices.  The 95% confidence interval 
was obtained by running 10,000 simulations in @Risk 5.0 (risk analysis software) 
using Excel 2007. For the length of stay, a non-parametric approach was used for 
matching patients with a jack-knife error estimate, and a normal approximation was 
then used for the standard error on the expected length of stay which was assumed 
to be approximately normal. 
The cost-benefit model compared the total 2019 costs to the healthcare system of a 
scenario with and without surveillance in place (healthcare provider’s perspective).  
The costs identified for surgical site infection following caesarean section were used 
to model the balance of surveillance costs versus savings over a five year period 
(with discounting of costs at 3.5% to reflect value over the time of the analysis)14 
using Microsoft Excel.  Different surveillance strategies were modelled, together with 
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three baseline infection risks and three potential average reductions in risk of 
infection between each surveillance period.  
The three average rates of reduction in infection risk were selected for the model 
given the reductions in caesarean section surgical site infection achieved during our 
cohort study (31%), also seen in other European single site studies (70-80% 
between interventions)15,16 and observed across European surveillance networks 
(e.g. approximately 33% over 4 years for United Kingdom, except England).17   
A range of scenarios were tested as follows: 
A. baseline infection risk of 5, 10 or 15%  
B. surveillance strategies of  
a. one 3-month surveillance quarter a year  
b. two 3-month surveillance quarters a year 
c. continuous surveillance (in 3-month periods) 
C. average reductions of 10, 20 or 30% in infection risk during each surveillance 
period. 
When calculating reductions in surgical site infection risk, the model reflected a 
constant reduction rate over the five year period of study whereby the risk for each 
surveillance period was iteratively calculated from the surgical site infection risk of 
the previous surveillance period.  A fourth surveillance strategy with a variable 
programme was also modelled: continuous surveillance for hospitals with a surgical 
site infection risk over 10%, 2 surveillance quarters a year for surgical site infection 
risk between 5 and 10% and one surveillance period a year for surgical site infection 
risk <5%. 
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The simulations assumed that average reductions in risk of disease were achieved 
through infection control measures taken during each surveillance period and 
sustained between surveillance periods.  The calculations also assumed an 
irreducible minimum infection risk of 3% could be reached at which point no further 
reductions in risk of infection would be included in the model and surveillance would 
be reduced to one quarter per year.   
Patient and Public Involvement 
Patients or the public were not involved in the design, conduct, reporting or 
dissemination of our research.  
This study falls within the remit of Public Health England to use patient data without 
explicit consent under Regulation 3 of the Health Service (Control of Patient 
Information) Regulations 2002 for surveillance and control of public health hazards 
explicitly including infectious disease. 
 
RESULTS 
Treatment costs 
The estimated 2010 costs to hospital and community of surgical site infection 
following caesarean section at a model hospital conducting 800 caesarean sections 
per year are shown in Table 2.  For the initial hospital stay (during which the 
caesarean section was performed) the difference in median length of stay for the 21 
patients with an infection detected during that inpatient stay, compared to those 
without an infection, was five days.  Using an alternative case-control paired 
matching approach to account for time at risk and differences in factors other than 
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the surgical site infection which may have increased length of stay (such as patient 
comorbidity), the number of excess days due to surgical site infection detected 
during the initial inpatient stay was calculated as 2.60 days (standard error 0.082).  
Costs associated with a) 2 patients subsequently readmitted to hospital for further 
treatment of infections detected during the initial inpatient stay and b) for 
readmission of 23 patients for surgical site infection, were derived from Healthcare 
Resource Group data. The most commonly identified codes associated with the 
readmission spell for infection of the patients in the cohort study were: ‘NZ05 
Antenatal and Post-natal investigation (0 days)’, ‘NZ08 Antenatal and Post-natal 
investigation (1 day or more)’. The cost to community healthcare of microbiological 
testing was estimated from the mean microbiology cost of £13.74 reported by the 
two NHS hospitals (including pay and consumables), together with the proportions of 
positive microbiology results recorded in the cohort study for community midwife 
detected and patient reported infections.  
The estimated hospital costs resulting from a 9.6% infection risk at a model hospital 
conducting 800 caesarean sections a year were estimated to be £13,544 with 
community costs estimated at £5,370, an overall cost of £18,914.  Uncertainty 
calculations (95% confidence interval) indicated a minimum of £11,521 and 
maximum £29,499 with the most influential parameters being infections detected on 
readmission, inpatient detected infections and incidence of readmission of the 
patients whose surgical site infection were already detected as inpatients.  The two 
main drivers of the uncertainty in the overall outcome were the incidence of 
readmission and the uncertainty around the excess length of stay.   
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Costs were inflated to 2019 prices (Table 2) using the OECD Consumer Prices Index 
for the United Kingdom (Total less food, less energy).18  This resulted in hospital 
costs of £16,047, Community costs of £6,363 and total cost of £22,409.  If the 9.6% 
infection risk identified in our cohort study was applied to the 179,475 caesarean 
sections performed annually in England (2018-19) this would be equivalent to 17,212 
infections resulting in an estimated cost of £5.0 million. The approximate cost per 
infection treated in hospital during inpatient or readmission stay was £1866 and was 
£93 for infections managed in the community by community midwives or general 
practitioners after discharge.  
Surveillance costs 
Information provided by participating hospitals indicated that a surveillance nurse 
would require time equivalent to two days a week for surveillance of 200 patients 
undergoing caesarean section for one quarter.  The estimated cost for one quarter of 
surveillance at the model hospital carrying out 800 caesarean sections a year was 
calculated at £3,747 including administrative costs (2010 prices) and £4,439 when 
inflated to 2019 costs (Table 3).   
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Table 2. Estimated annual hospital and community costs to the NHS arising due to surgical site infection following caesarean section for a model 
hospital conducting 800 caesarean sections per year  
Treatment stage  Item Estimate (95% CI)* 
Hospital 
costs (£) 
Community 
costs (£) 
Total costs 
(£) 
(95% CI)* 
†Inflated 
costs 
Infections detected during inpatient stay a Excess length of stay (days) 2.6 (2.44 to 2.76)      
 b Value per bed day £444.00       
 c No. cases (0.51% of 800 women) 4.1 (2.3 to 5.8)      
  Total = (a*b*c)   £4,722.82    £5,595.68 
          
Inpatient detected SSI subsequently readmitted a Average HRG cost per spell £1,092.20       
 b Spells per patient 1       
 c No. cases (0.05% of 800 women) 0.4 (0 to 1)      
  Total = (a*b*c)   £428.14    £507.27 
          
Infections detected at readmission a Average HRG cost per spell £1,387.67       
 b Spells per patient 1.35       
 c No. cases (0.56% of 800 women) 4.5 (2.7 to 6.2)      
  Total = (a*b*c)   £8,392.63    £9,943.74 
          
Infections detected by community midwife a 1 extra midwife visit  £63.00       
 b 1 extra visit to GP  £30.00       
 c 1 course antibiotics  £4.27       
 d Microbiology (£13.74)*43% £5.91       
 e No. cases (5.31% of 800 women) 42.4 (37.0 to 47.8)      
  Total (a+b+c+d)*e    £4,383.01   £5,193.07 
          
Self-reported infections a 1 extra visit to general practitioner £30.00       
 b 1 course antibiotics (£4.27) £4.27       
 c Microbiology (£13.74)*30% £4.12       
 d No. cases (3.21% of 800 women) 25.7 (21.4 to 30.0)      
  Total = (a+b+c)*d    £987.14   £1,169.58 
          
  Total costs   £13,544 £5,370 £18,914 
(£11,521 to 
£29,499) 
£22,409 
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*CI=Confidence Interval.   †Inflated to 2019 prices using UK Consumer Price Index – Total less food, less energy (OECD Data) 
HRG=Healthcare Resource Group, SSI=Surgical site infection 
 
 
Table 3. Estimated costs for a 3-month surveillance period for surgical site infection following caesarean section for a model hospital conducting 
800 caesarean sections per year  
Surveillance 
 
Item Surveillance  Total Inflated costs† 
Surveillance 
nurse a 
 0.4 equivalent Band 6 Surveillance nurse (24% on 
costs)  £14,614   
 b 1 surveillance quarter 0.25   
  Total (a*b)  £3,653.54 £4,328.78 
      
Administration  a Stationery/photocopying/stamps/phone calls  £0.47   
 b Patients in surveillance quarter 200   
  Total (a*b)  £93.00 £110.19 
  Total cost  £3,746.54 £4,438.97 
†Inflated to 2019 prices using UK Consumer Price Index – Total less food, less energy (OECD Data) 
 
 
 
17 
 
Modelling cost savings from surveillance 
As might be expected, the model simulations estimating the balance of surveillance 
expenditure versus savings covering a period of 5 years indicated that surgical site 
infection risk reduced more quickly for the continuous surveillance strategy than for 
either one or two quarters a year surveillance where the same baseline infection risk 
and reductions in risk of infection were applied (Figures 2-4).   
Where the hospital baseline infection risk was 10%, similar to the mean surgical site 
infection risk in the cohort study, savings over the period of simulation were greater 
than the costs of surveillance for all the surveillance strategies where reductions of 
20 or 30% in the risk of infection were achieved.  Breakeven was achieved by the 
end of Year 2 (or sooner) where reductions of 30% between successive surveillance 
periods were applied and by the end of Year 3 (or sooner) for reductions of 20% 
(Figure 3).  Net savings of £26,021 over the five year period were achieved for a 
strategy of continuous surveillance with a 20% reduction in infection risk.  The 
simulation for a hospital with a baseline infection risk of 5% indicated that savings 
from reducing surgical site infection risk did not offset the costs of surveillance for 
any of the surveillance strategies.  
For a hospital with a baseline surgical site infection risk of 15%, all of the 
surveillance strategies achieved savings greater than the costs of surveillance over 
the 5 year period of the simulation when reductions in infection risk of 10, 20 or 30% 
were applied.  Breakeven was achieved by the end of Year 2 (or sooner) where 
reductions of 20% and 30% at each surveillance period were applied (Figure 4).  A 
saving of £63,217 over the period of simulation was obtained for a 15% baseline 
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infection risk achieving a 20% reduction in infections at each surveillance period and 
employing a continuous surveillance strategy. 
When the variable surveillance strategy was modelled (Figure 5) this responsive 
strategy estimated a net saving of £63,234 would be achieved for a hospital with a 
15% baseline infection risk achieving a 20% reduction in infections at each 
surveillance period (£26,696 savings for 10% infection risk with 20% reductions).  
For hospitals with a 15% baseline infection risk, breakeven points for the variable 
surveillance strategy were slightly later compared to the fixed surveillance strategies 
of one or two surveillance periods a year, due to the continuous surveillance 
component of the variable strategy.  However, for a 10% baseline infection risk, 
breakeven was earlier or at the same time for the variable surveillance strategy 
compared to the original fixed surveillance strategies. 
Overall breakeven was reached within the 5 year simulation period with the variable 
surveillance strategy for scenarios where hospitals had a baseline infection risk of 10 
or 15% (Figures 6-8).  The variable surveillance strategy achieved higher (5/9 
scenarios) or similar net savings (1/9 scenarios) compared to the original 
surveillance strategies for the equivalent baseline infection risk and reductions in risk 
of infection.  The variable surveillance strategy for hospitals with a 5% baseline risk 
of infection was equivalent to the one surveillance period a year strategy and 
therefore resulted in equal losses (3/9 scenarios).  
A tool has been designed, based on the costs identified in this study for caesarean 
section, to predict the time to breakeven for a model hospital employing the variable 
surveillance strategy and applying self-selecting baseline infection risk, predicted 
reductions in infection and volume of surgery (supplementary material).   
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DISCUSSION 
Our study estimated that surgical site infections in caesarean section cost the 
National Health Service in England £5.0 million a year, equating to £22,409 for a 
typical hospital conducting 800 caesarean sections per year. Through capture and 
assessment of the costs of surveillance, our model showed that the benefits of a 
surveillance strategy can outweigh the costs through reductions in incidence of 
surgical site infections.  
Excess length of stay of patients with infection compared to patients without is 
frequently used as a proxy for combined inpatient attributable costs.  As median 
length of stay for caesarean section patients was 3 days at the time of the study, and 
median time to infection was 10 days, the majority of surgical site infections would 
have occurred after discharge.  However, if a woman remains in hospital for reasons 
other than surgical site infection there is a chance she might develop a surgical site 
infection which would otherwise have been detected and managed in the community 
by her midwife or general practitioner. Therefore, a naïve comparison of length of 
stay between patients with and without a surgical site infection would have produced 
an overestimate because it would not disentangle the increased chance of detecting 
an infection for those patients with a prolonged length of stay due to other reasons.19 
20  A suitable calculation method should account for patient heterogeneity and timing 
of events to avoid biasing results.  A multistate model estimate which accounted for 
the time-dependent bias was considered, however this did not naturally incorporate 
patient heterogeneity.  An alternative option was to use a confounder and time 
matching approach, where suitable control patients should be "at risk" of acquiring 
an infection at the time of infection of the corresponding case, which can be satisfied 
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by using the time-to-infection as an additional matching criteria.  The advantage of 
the method used in this study, of matching infected patients with similar uninfected 
patients with comparable length of post-operative stay prior to infection, is that it 
produced a more accurate assessment of the excess length of stay directly 
attributable to the surgical site infection (2.6 days) than the average excess length of 
stay (median 5 days). 
The largest contribution to the overall costs (and the uncertainty) for the model 
hospital is the excess post-delivery length of stay and the readmission of patients.  
This equates to approximately £1,866 per infection detected during the inpatient stay 
or leading to readmission. There are few studies describing costs for surgical site 
infection following caesarean section and comparisons are hampered by differences 
in methodology.21 22  The cost of £1,866 in this study is lower than the median cost of 
£3,716 calculated by Jenks et al.21 There were differences between the two studies 
in length of stay calculated to be attributable to surgical site infection between (4 
days versus 2.6 in this study). Our study used a case-matching methodology to 
account for both time at risk and extraneous factors which would lead to an 
overestimation of excess length of stay. This, along with our inclusion of data from 
multiple centres as opposed to a single site may account for differences in our cost 
estimates. In our multicentre study the majority of infections (52%) detected at 
readmission and 24% of those detected during the initial inpatient stay were the 
more serious infections (deep incisional or organ/space) which are likely to require 
more extensive treatment, such as debridement or re-suturing, than superficial 
infections.  In contrast only 13% of midwife detected surgical site infections were 
deep or organ/space infections.   
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Previous studies have focussed primarily on hospital costs.21-23  By including an 
estimate of the costs in the community in this analysis a more representative 
estimate of overall economic burden to the health service was achieved.  More than 
28% of the economic burden arose in the community where the majority of these 
infections are managed.  A study of breast surgery in England which included post-
discharge follow-up also found a similar proportion of costs incurred in the 
community (31%).24  In contrast a study conducted in Scotland in 2001, using actual 
rather than estimated bed days and general practitioner visits, identified 11% of 
treatment costs resulting from surgical site infection occurred in the community.25  
However, that study included non-obstetric surgical procedures (which would not 
have incurred midwife costs).  
Limitations 
As well as applying the National Schedule Reference Costs to provide the average 
cost of hospital stay, rather than actual observed expenditure, various assumptions 
have been made in this study including the number of extra midwife and general 
practitioner appointments resulting from infection.  However, there are likely to be 
additional costs to those outlined.  For example, some of the patients readmitted for 
more serious infections may also require a hospital outpatient follow-up appointment 
or further general practitioner visits.  Also, additional outpatient appointments and 
more than one course of antibiotics may be needed to treat infections identified by 
midwives and general practitioners.  Given that our analysis was based on 
healthcare utilisation, excluding additional costs (direct and indirect) incurred by the 
affected women or their carers, the true costs associated with these infections are 
likely to be higher than our estimates.  The intangible costs resulting from the pain 
and suffering of the women were not assessed although wound infections and 
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endometritis following caesarean section have been reported to increase anxiety and 
delay physical recovery for these women, with consequent impact on their ability to 
care for their new born.26  Whilst the majority of women will be on maternity leave, 
family members or other carers may require time off work to look after the patient or 
to provide childcare for the new-born or other children.  An extensive prospective 
study would be required to gain more comprehensive information on the detailed 
costs associated with surgical site infection following caesarean section.   
Although the reductions in surgical site infection risk in the model are supported by 
the data from the cohort study (Figure 1) the surveillance was only repeated once 
and two of hospitals did not achieve reductions.  Therefore, there is no guarantee 
that such reductions would be sustained over time.  Additionally, decreases in risk of 
infection between surveillance cycles will in reality vary over time within a given 
hospital and a constant rate of reduction in infections is unlikely to offer a true 
reflection of this pattern.  This study has applied an average reduction rate in risk of 
infection but, as further information becomes available on patterns of reduction, the 
model can be adapted. 
There may be additional costs associated with setting up and running surveillance 
such as training community midwives and feedback meetings with surgeons but 
these costs can be minimised by incorporating time into existing infection prevention, 
maternity or surgical meetings. Whilst it could be argued that surveillance drives 
adherence to infection control practices that should be in place already, where such 
measures are not in place additional infection prevention and control measures may 
incur costs.  However, changes to many infection prevention measures may be cost-
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neutral and additional costs for specific interventions can be considered once 
identified.   
The community costs estimated in this study are not incurred by the hospital and, as 
hospitals would not realise any savings from community care by reducing these 
infections, this could be a disincentive to hospitals carrying out surveillance and 
setting up new infection control measures. 
Implications for surveillance 
Surgical site infection surveillance schemes which include feedback of results to 
surgeons have been found to reduce risk of infections 27 28 and individual hospitals 
have successfully reduced infection risk by applying measures to improve practice.15 
29  The NICE30 and WHO31 guidelines for preventing surgical site infection 
recommend various approaches to reduce infection risk including the timing of 
antimicrobial prophylaxis, avoiding shaving, antiseptic skin preparation, maintaining 
patient homeostasis, covering wounds with an interactive dressing and prevention of 
hypothermia.32  Whilst health services may aim to achieve a zero risk of infection, it 
is likely that there is an irreducible minimum risk for some surgical categories beyond 
which there will be limited opportunities for further reductions.  Such a possibility was 
built into the model.  In some hospitals, high infection risks may be due to underlying 
systemic problems and reductions in infection risk may take longer in these more 
complex situations.  Local needs of individual hospitals will need to be assessed.   
This study estimated the cost of surveillance for one 3-month period as £4,439 for a 
model hospital conducting 800 caesarean sections a year.  A continuous 
surveillance programme would provide a more rapid decrease in infection risk, when 
accompanied by improvements in care, than surveillance strategies of one or two 
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quarters a year. However, although the continuous surveillance model achieved 
savings for hospitals with higher baseline infection risk, it did not achieve the 
greatest balance of saving against costs of surveillance over the 5 year simulation 
period for scenarios with a 10% reduction in infections between surveillance periods.  
The variable surveillance model achieved similar or greater savings or smaller losses 
for all baseline infection risks.  Extrapolating from these findings, hospitals could 
consider a variable surveillance strategy of continuous surveillance for hospitals with 
high risk of infection (greater than 10%) to rapidly reduce infections and patient harm 
as quickly as possible.  Surveillance for caesarean section could then be reduced to 
two quarters a year once the infection risk has decreased to 10% and to one quarter 
per year when the infection risk declines to 5% to maximise savings.  In terms of cost 
saving this approach is supported by the model estimates for such a variable 
surveillance programme identified by this study.  A minimum surveillance strategy of 
one quarter a year would then be useful to reinforce infection control measures and 
provide continued vigilance to sustain low levels of infection.  However, the strategy 
outlined in this model may not be applicable to other surgical categories, particularly 
those with a low infection risk.   
Although a variable surveillance strategy can be less costly and can be tailored to 
the baseline infection risk of a hospital, conducting continuous surveillance has 
advantages.  These include having well established surveillance systems with 
methodology embedded in practice, and providing a more precise estimate of 
infection risk where surgical volumes are low.  Additional savings to those presented 
in this study could be achieved through reducing surveillance costs, for example 
through use of patient-facing digital technologies, currently under development, to 
collect patient-reported infections. 33  
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Patient outcomes 
The number of caesarean sections performed each year in England has been rising 
since the 1980s2 accompanied by an increase in the proportion of women of child 
bearing age who are obese.34  High BMI has been identified as a key risk factor for 
surgical site infection following caesarean section.6  This means that with rising 
obesity surgical site infections are likely to become an increasing burden for the 
health service.  Reducing the risk of infections following caesarean section is an 
important health issue for these women who are otherwise generally young and 
healthy.   
The multi-centre cohort study identified 1 in 10 women with surgical site infection 
following caesarean section.6  There is currently no national surveillance for surgical 
site infection following caesarean section in England, although it is mandatory in 
Scotland, Wales and Northern Ireland and there is considerable support from 
hospitals to introduce this in England.35 36   
Although costs incurred by surgical site infection following caesarean section are 
lower than those associated with infections following orthopaedic and other surgical 
categories,37-40 infections post-caesarean can still lead to serious outcomes,7 41 42 
and may give rise to high cost clinical negligence claims.43  However, the decision to 
attempt to reduce risk of surgical site infection is not solely about cost saving.  
Hospitals have a duty to avoid harm to the patient, reduce antibiotic consumption 
and improve patient experience. 
Conclusion 
Surgical site infection following caesarean section causes pain and anxiety to new 
mothers and incurs a financial burden to the healthcare system in both community and 
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hospital healthcare settings.  Integrating caesarean section surveillance into the 
national surveillance programme would provide hospitals with the infrastructure (and 
national benchmark) for reducing infection by feeding back data and there by 
empowering staff to take action to improve patient care and potentially reduce costs.  
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Figure Legends 
Figure 1. Change in surgical site infection (SSI) risk between consecutive 3 month 
surveillance periods for 7 hospitals during the multi-centre caesarean section study 
Figure 2. Balance of surveillance cost versus savings from reductions of 10, 20 and 
30% per surveillance period for surveillance strategies of one quarter a year, two 
quarters a year and continuous surveillance for starting surgical site infection (SSI) 
risk of 5%  
Figure 3. Balance of surveillance cost versus savings from reductions of 10, 20 and 
30% per surveillance period for surveillance strategies of one quarter a year, two 
quarters a year and continuous surveillance for starting surgical site infection (SSI) 
risk of 10%  
Figure 4. Balance of surveillance cost versus savings from reductions of 10, 20 and 
30% per surveillance period for surveillance strategies of one quarter a year, two 
quarters a year and continuous surveillance for starting surgical site infection (SSI) 
risk of 15%  
Figure 5.  Balance of surveillance cost versus savings from reductions in surgical 
site infection risk of 10, 20 and 30% per surveillance period for baseline surgical site 
infection (SSI) risk of 10 or 15% using a variable surveillance strategy  
(continuous surveillance when the infection risk is above 10%, two quarters per year 
surveillance for infection risk between 5 and 10% and one quarter per year 
surveillance for infection risk below 5%)  
Figure 6. Cumulative discounted prevented costs against costs of surveillance after 
5-year surveillance programme - 15% Baseline surgical site infection risk 
Figure 7. Cumulative discounted prevented costs against costs of surveillance after 
5-year surveillance programme - 10% Baseline surgical site infection risk 
Figure 8. Cumulative discounted prevented costs against costs of surveillance after 
5-year surveillance programme - 5% Baseline surgical site infection risk 
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